You are here

News

Comment

Discuss

Coverage of the latest news and updates from ongoing clinical trials from various sources.

March 24, 2017

Cedars-Sinai investigators have identified a stem cell-regulating gene that affects tumor growth in patients with brain cancer and can strongly influence survival rates of patients.

March 24, 2017

Mesoblast Ltd., a producer of cell-based therapies based in Melbourne, Australia, recently released the results of two studies that it says show promise for its stem cell products in treating rheumatoid arthritis and chronic lower back pain.

March 22, 2017

Israeli biotechnology company Kadimastem has been granted a patent from the United States Patent and Trademark Office for its technology in the field of cell-based treatment for diseases of the nervous system. The U.S. patent joins additional patents granted in Israel and&nbsp

March 22, 2017

Chronic pain from nerve injury is common and often debilitating. Current treatment options for neuropathic pain include physical, cognitive, behavioral, pharmacological, interventional and surgical therapies.

March 20, 2017

Longeveron, a stem cell research company focused on biological solutions for age-associated diseases, has announced the completion of enrollment in the first phase of its clinical research trial of Longeveron allogeneic human mesenchymal stem cells (LMSCs®) to treat Alzheimer's disease.  &nb

March 20, 2017

Three people with macular degeneration were blinded after undergoing an unproven stem cell treatment that was touted as a clinical trial in 2015 at a clinic in Florida.

March 16, 2017

Cedars-Sinai investigators have identified a stem cell-regulating gene that affects tumor growth in patients with brain cancer and can strongly influence survival rates of patients.

March 13, 2017

Vitamin C is up to 10 times more effective at stopping cancer cell growth than pharmaceuticals such as 2-DG, according to scientists in Salford, UK.

March 13, 2017

Targeting cancer stem cells may be a more effective way to overcome cancer resistance and prevent the spread of squamous cell carcinoma, the most common head and neck cancer and the second-most common skin cancer, according to a new study by cancer researchers at the UCLA School of Dentistry.

March 8, 2017

A Phase III clinical trial involving 101 centers in 21 countries revealed the monoclonal antibody blinatumomab to be more effective than standard chemotherapy for treatment of advanced acute lymphoblastic leukemia (ALL).

Pages